AI brings venture capital back into biotech

Venture capital is increasingly turning its attention to a new generation of biotech startups that are built around artificial intelligence rather than traditional lab-based research. Unlike conventional biotech companies, which rely on long development cycles, expensive laboratory infrastructure, and high uncertainty, these AI-native firms operate as software-first organizations where machine learning is central to their operations. They leverage large-scale biological datasets, automate workflows, and create reusable platforms instead of focusing on single-product pipelines, signaling a fundamental shift in how biotech innovation is structured.

This change mirrors broader trends in venture capital. In 2025, more than 60% of global VC investment was directed toward AI-related companies, underscoring the growing dominance of artificial intelligence in investment decisions. Within biotech, companies that can deeply integrate AI into their processes are becoming significantly more attractive to investors than those following traditional approaches, as the technology reduces risk and accelerates research outcomes.

Historically, biotech investments carried substantial risk due to long timelines and uncertain results. AI is beginning to change this dynamic by improving prediction accuracy in drug discovery, reducing failed experiments, and speeding early-stage validation. As a result, investors are increasingly confident in the predictability and scalability of biotech ventures, making the sector more appealing for strategic capital allocation.

The adoption of software is also making biotech more scalable. Where traditional approaches required starting from scratch for each new drug or therapy, AI-powered platforms enable companies to reuse models across multiple disease areas, automate research workflows, and continuously improve through data. This approach transforms biotech into a model more akin to software-as-a-service, emphasizing iteration and compounding value over time, which resonates strongly with investors familiar with software-driven growth.

Capital is increasingly concentrating around platform companies rather than dispersed, experimental startups. Investors are now favoring fewer, larger funding rounds for companies with strong technical differentiation, proprietary datasets, and integrated AI infrastructure. This trend reflects a broader venture capital strategy that prioritizes conviction-based investing and the backing of businesses capable of delivering measurable outcomes rather than speculative ideas.

At the heart of this transformation is the convergence of biology and software. Modern biotech companies no longer separate “wet lab” research from tech teams. Instead, they operate as integrated systems where data flows continuously between experiments and algorithms, AI models guide lab decisions in real time, and software platforms orchestrate the entire research lifecycle. This convergence is fostering closer collaboration between startups, large pharmaceutical companies, and technology providers, particularly in areas such as AI-driven drug discovery and synthetic biology.

The resurgence of venture capital in biotech is part of a larger shift across multiple sectors, including healthtech, cybersecurity, and enterprise software. However, investors today are more discerning, focusing on AI-driven systems capable of producing real-world outcomes rather than funding isolated point solutions. This marks a maturation of the market, with measurable impact and execution taking precedence over hype and potential.

The implications for biotech are profound. Companies that integrate biological expertise with data infrastructure and AI capabilities are positioned to lead the industry. Talent demand is also evolving, with software engineers, AI specialists with biological knowledge, and hybrid teams increasingly sought after. Speed has become a key competitive advantage, favoring companies that can iterate rapidly, process large volumes of data, and automate decision-making.

Venture capital is playing a more strategic role as well, shaping company strategy, enabling partnerships, and helping build ecosystems around AI-driven platforms. The return of investment is not merely a cyclical rebound but a signal of a new era in biotech. The industry is moving from a slow, lab-centered model to a fast, software-powered ecosystem, and AI-native companies are at the forefront, attracting capital, talent, and partnerships at an accelerating pace. For investors, the message is clear: the future of biotech will be defined not just by molecules, but by the software systems that design, test, and scale them.